Beneficial effects of luseogliflozin on lipid profile and liver function in patients with type 2 diabetes mellitus (BLUE trial): a single-center, single-arm, open-label prospective study

Table 2 Primary study endpoints at 24 weeks (n = 25)

	0 weeks	24 weeks	Amount of change	p-value
HbA1c (%)	7.8 ± 0.6	7.2 ± 0.8	− 0.6 ± 0.9	0.003*
TG (mg/dL)	175.0 [147.0–219.0]	138.0 [93.0–172.0]	− 30.0 [− 75.0 to − 10.0]	0.007*
Total cholesterol (mg/dL)	172.8 ± 32.0	175.1 ± 37.6	2.3 ± 19.3	0.554
HDL-C (mg/dL)	47.4 ± 7.1	52.5 ± 9.5	5.2 ± 6.7	< 0.001*
LDL-C (mg/dL)	91.9 ± 30.4	93.5 ± 34.0	1.6 ± 14.4	0.584
non-HDL-C (mg/dL)	125.4 ± 31.4	122.6 ± 35.1	− 2.8 ± 19.0	0.468
ApoB (mg/dL)	82.4 ± 19.6	82.6 ± 22.6	0.2 ± 15.6	0.960
ApoA-1 (mg/dL)	146.4 ± 19.8	154.2 ± 25.8	7.9 ± 15.5	0.018*
RLP-C (mg/dL)	8.1 ± 3.0	6.3 ± 3.6	− 1.8 ± 3.2	0.010*
TG/HDL-C ratio	3.9 [2.8–4.6]	2.6 [1.7–3.4]	− 1.0 [− 1.9 to − 0.4]	0.024*

Data are presented as the mean ± standard deviation or median (interquartile range)
*Indicates statistical significance. Paired t-test, (versus 0 weeks) *p < 0.05; Wilcoxon signed-rank test, (versus 0 weeks) *p < 0.05
“Amount of change” is the change between 0 and 24 weeks
HbA1c: glycated hemoglobin; TG: triglyceride; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; Apo: apolipoprotein; RLP-C: remnant-like lipoprotein cholesterol

ISSN: 1758-5996